Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
BI 836880 + Ezabenlimab for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1
Columbus, Ohio
This trial is testing a combination of two drugs, BI 836880 and ezabenlimab, to see if they can shrink tumors in people with advanced non-small cell lung cancer or other types of advanced cancer.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.